📰 Pharma Mar News
Page 3 - Pharma Mar News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pharma Mar. Real-time updates on events, politics, business and more.
March 15, 2023
DUBLIN, March 15, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present five new abstracts at the American Association
March 15, 2023
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present five new abstracts at the...
February 13, 2023
Achieving success is not an ea
February 2, 2023
Achieving success is not an ea
October 19, 2022
Pune, Maharashtra, October 19 2022 (Wiredrelease) Market.Biz –:What Is The Current Situation Of Marine Derived Drugs Global Market After Covid 19, The Russia-Ukraine War, and The Sri Lankan Economy CrisisThe Marine Derived Drugs Market research report is a professional analysis that includes industry, type, applicat...
May 12, 2022
Pharma Mar (OTCMKTS:PHMMF – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline […]
April 28, 2022
(PLX AI) - Pharma Mar says good performance of the oncology business led to recurring revenues (sales plus royalties), growing by 7% in the first three months of the year to EUR 46 million.• Q1 net income
March 24, 2022
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the first patient was enrolled in EMERGE-201, a Phase 2 clinical trial evaluating the...
March 24, 2022
Open-label basket trial will assess the safety and efficacy of Zepzelca in patients with advanced urothelial carcinoma, large cell neuroendocrine carcinoma of the lung, or homologous recombination
March 9, 2022
Pharma Mar (OTCMKTS:PHMMF – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline […]